Dr. Chun Huang 黄纯
Chief Physician
Department of Medical Oncology I, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical oncology for lung cancer, breast cancer, malignant lymphoma, and urogenital and digestive system tumors. Specializes in chemotherapy and molecular targeted therapy for thoracic tumors, including thymoma, and malignant pleural effusion and ascites.
Dr. Huang holds a PhD in Oncology from Tianjin Medical University and completed joint doctoral training at Moffitt Cancer Center (2012). With 16 years in medical oncology since 1997, Dr. Huang participated in US Department of Defense and National Natural Science Foundation projects. Awards include the 2007 and 2011 Tianjin Science and Technology Progress Awards.
Professional roles
- Member, American Association for Cancer Research (AACR)
- Member, Chinese Society of Clinical Oncology (CSCO)
- Member, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Huang Chun). Papers usually list the name as Chun Huang or Huang C.
Selected publications
20 papers on PubMed matched by name and affiliation; 7 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncol Lett, 2025 (senior author): Efficacy and safety of antibody drug conjugate therapy in patients with human epidermal growth factor receptor 2-positive non-small cell lung cancer: A single-arm systematic review and meta-analysis. PubMed 40861101
- Front Pharmacol, 2024 (senior author): A case report: Pathological complete response to neoadjuvant lorlatinib for Epithelioid inflammatory myofibroblastic sarcoma with EML4-ALK rearrangement. PubMed 39144623
- Ann Transl Med, 2022 (senior author): Successful re-challenge of dabrafenib-trametinib combination therapy in advanced BRAF (V600E)-mutant non-small cell lung cancer after previous cytotoxic chemotherapy, targeted therapy, and immunotherapy: a case report. PubMed 36267742
- Thorac Cancer, 2020 (senior author): Sequential ALK inhibitor treatment benefits patient with leptomeningeal metastasis harboring non-EML4-ALK rearrangements detected from cerebrospinal fluid: A case report. PubMed 31766077
- J Cancer, 2019 (senior author): Comparison of Clinicopathological Features and Prognosis between ALK Rearrangements and EGFR Mutations in Surgically Resected Early-stage Lung Adenocarcinoma. PubMed 30662526
- Oncotarget, 2017 (senior author): Worse disease-free, tumor-specific, and overall survival in surgically-resected lung adenocarcinoma patients with ALK rearrangement. PubMed 29156778
- Zhongguo Fei Ai Za Zhi, 2017 (senior author): [Clinical Advanced in Early-stage ALK-positive Non-small Cell Lung Cancer Patients]. PubMed 28228224
- Target Oncol, 2015 (first author): Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer. PubMed 24838619
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion